<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A highly aggressive subclone of the human CALLA+C <z:chebi fb="0" ids="30214">mu+</z:chebi> pre-B <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) cell line NALM-6 (designated NALM-6-UM1) caused disseminated and fatal <z:hpo ids='HP_0001909'>leukemia</z:hpo> in CB.17 mice with <z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> (<z:mp ids='MP_0002536'>SCID</z:mp>) </plain></SENT>
<SENT sid="1" pm="."><plain>An intravenous challenge with 1 x 10(6) (NALM-6-UM1 cells caused 15 of 27 (56%) <z:mp ids='MP_0002536'>SCID</z:mp> mice to become paraplegic at 31 +/- 2 days (median = 33 days) and 27 of 27 (100%) mice to die of disseminated <z:hpo ids='HP_0001909'>leukemia</z:hpo> at 38 +/- 1 days (median = 39 days) </plain></SENT>
<SENT sid="2" pm="."><plain>We used this <z:mp ids='MP_0002536'>SCID</z:mp> mouse model of aggressive human <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre-B ALL</z:e> to evaluate the in vivo antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (<z:mp ids='MP_0010998'>PAP</z:mp>) immunotoxin </plain></SENT>
<SENT sid="3" pm="."><plain>A 3-day treatment with nontoxic doses of B43-<z:mp ids='MP_0010998'>PAP</z:mp> markedly reduced the incidence of <z:hpo ids='HP_0010550'>paraplegia</z:hpo> and improved event-free survival (EFS) in <z:mp ids='MP_0002536'>SCID</z:mp> mice challenged with 1 x 10(6) NALM-6-UM1 <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre-B ALL</z:e> cells, as reflected by significantly higher cumulative proportions of mice free of <z:hpo ids='HP_0010550'>paraplegia</z:hpo> or alive at 1 to 7 months, as compared with phosphate-buffered saline (PBS) treated control mice </plain></SENT>
<SENT sid="4" pm="."><plain>The Kaplan-Meier estimates and standard errors of the probability of developing <z:hpo ids='HP_0010550'>paraplegia</z:hpo> after inoculation of 1 x 10(6) NALM-6-UM1 cells was 64% +/- 10% for PBS-treated mice (median time to <z:hpo ids='HP_0010550'>paraplegia</z:hpo> = 37 days) (N = 27), 18% +/- 8% for mice treated with 15 micrograms B43-<z:mp ids='MP_0010998'>PAP</z:mp> (5 micrograms/mouse/d x 3 days) (N = 23) and 5% +/- 5% for mice treated with 30 micrograms B43-<z:mp ids='MP_0010998'>PAP</z:mp> (10 micrograms/mouse/d x 3 days) (N = 21) </plain></SENT>
<SENT sid="5" pm="."><plain>While 27 of 27 PBS-treated control <z:mp ids='MP_0002536'>SCID</z:mp> mice died of <z:hpo ids='HP_0001909'>leukemia</z:hpo> at 38 +/- 1 days (range = 24 to 54 days), only 16 of 44 B43-<z:mp ids='MP_0010998'>PAP</z:mp>-treated mice developed <z:hpo ids='HP_0001909'>leukemia</z:hpo> at 74 +/- 12 days (range = 30 to 182 days), consistent with greater than or equal to 6 logs kill of clonogenic NALM-6-UM1 cells in 64% of <z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="6" pm="."><plain>The Kaplan-Meier estimates and standard errors of the probability of long-term EFS after inoculation of 1 x 10(6) NALM-6-UM1 cells were 65% +/- 10% for mice treated with 15 micrograms B43-<z:mp ids='MP_0010998'>PAP</z:mp> and 60% +/- 11% for mice treated with 30 micrograms B43-<z:mp ids='MP_0010998'>PAP</z:mp> with a median survival time of greater than 7 months for both groups </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, neither unconjugated B43 monoclonal antibody nor the anti-T-cell immunotoxin G17.2 (anti-CD4)-<z:mp ids='MP_0010998'>PAP</z:mp> decreased the incidence of <z:hpo ids='HP_0010550'>paraplegia</z:hpo> or improved EFS.(ABSTRACT TRUNCATED AT 400 WORDS) </plain></SENT>
</text></document>